With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer real hope for every patient with a cure for cancer.

The Personalized Cancer Vaccine Summit returns to Boston for the third year bringing together the top industry players developing individualized approaches across several modalities

Beacon Cancer Vaccine’s expert research analyst, Gloria Castro, will be taking to the stage to deliver an overview of the current drug and trial landscape, delving into the shifting landscape of disease focus in preclinical vs. clinical drug development and see how personalized cancer vaccines are breaking ground in precision medicine. Gain insights into therapeutic class distribution and trial phases driving these innovative treatments forward. Find out the full details today.

Join us and 80+ key stakeholders at the ultimate learning and networking forum to help advance your patient-centric pipelines toward the clinic and regulatory approval.